RIVASA 81 MG EC TABLET (DELAYED-RELEASE)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

ACETYLSALICYLIC ACID

متاح من:

LABORATOIRE RIVA INC.

ATC رمز:

B01AC06

INN (الاسم الدولي):

ACETYLSALICYLIC ACID

جرعة:

81MG

الشكل الصيدلاني:

TABLET (DELAYED-RELEASE)

تركيب:

ACETYLSALICYLIC ACID 81MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

1000

نوع الوصفة الطبية :

OTC

المجال العلاجي:

SALICYLATES

ملخص المنتج:

Active ingredient group (AIG) number: 0101169013; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2014-02-17

خصائص المنتج

_RIVASA 81 MG EC - Product Monograph _
_ _
_Page 1 of 44 _
PRODUCT MONOGRAPH
RIVASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville,
Quebec
J7C 3V4
www.labriva.com
Date of Preparation:
February 17, 2014
Date of Revision:
September 14, 2022
Control Number: 266709
_RIVASA 81 MG EC - Product Monograph _
_ _
_Page 2 of 44 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE
REACTIONS.............................................................................................
6
DRUG INTERACTIONS
.............................................................................................
7
DOSAGE AND ADMINISTRATION
..........................................................................
9
OVERDOSAGE
.........................................................................................................10
ACTION AND CLINICAL
PHARMACOLOGY.........................................................11
STORAGE AND STABILITY
....................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................12
PART II: SCIENTIFIC INFORMATION
..........................................................................
13
PHARMACEUTICAL INFORMATION
.....................................................................13
CLINICAL TRIALS
...................................................................................................14
DETAILED
PHARMACOLOGY.........